Press release
Graft versus host disease Pipeline Report 2023: Treatment Drugs, Emerging Therapies with Over 60 Key Companies Working in the Domain by DelveInsight | Biocon, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, R
Graft versus host disease Pipeline
DelveInsight's "Graft versus host disease Pipeline Insight - 2023" report provides comprehensive global coverage of available, marketed, and pipeline GVHD therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Graft versus host disease pipeline domain.
Request for sample page: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Graft versus host disease Pipeline Report
• DelveInsight's Graft versus host disease pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Graft versus host disease treatment.
• Leading Graft versus host disease (GVHD) companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others are evaluating new drugs for GVHD to improve the treatment landscape.
• Promising Graft versus host disease pipeline therapies in various stages of development include ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.
Graft versus host disease Overview
Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient's body cells. "Graft" refers to transplanted, or donated tissue, and "host" refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT).
Find out more about Graft versus host disease treatment drugs @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Graft versus host disease Pipeline Drugs:
• Itolizumab: Biocon
• T-Guard: Xenikos
• MaaT013: MaaT Pharma
• Axatilimab: Syndax Pharmaceuticals
• TQ 05105: Chia Tai Tianqing Pharmaceutical Group
• And Many Others
Graft versus host disease Therapeutics Assessment
The Graft versus host disease pipeline report proffers an integral view of GVHD emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Graft versus host disease pipeline therapies @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Graft versus host disease Pipeline Report
• Coverage: Global
• GVHD Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• GVHD Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Graft versus host disease Therapeutics Assessment By Route of Administration: Intravenous, Oral, Rectal.
• Key GVHD Companies: Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others
• Key GVHD Pipeline Therapies: ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.
Dive deep into rich insights for new drugs for GVHD treatment; visit @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
• Introduction
• Executive Summary
• Graft versus host disease (GVHD): Overview
• What is Graft versus host disease (GVHD)?
• Types of Graft versus host disease (GVHD)
• Causes
• Epidemiology and Risk Factors
• Disease Management
• GVHD Pipeline Therapeutics
• Comparative Analysis
• Graft versus host disease Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
• Graft versus host disease (GVHD)- DelveInsight's Analytical Perspective
• Late Stage Products (Preregistration)
• Comparative Analysis
• Itolizumab: Biocon
• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report…..
• Mid Stage Products (Phase II)
• Comparative Analysis
• ASC930: ASC Therapeutics
• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I/II)
• TQ 05105: Chia Tai Tianqing Pharmaceutical Group
• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I)
• Comparative Analysis
• Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report…..
• Inactive Products
• Comparative Analysis
• Graft versus host disease (GVHD) Key Companies
• Graft versus host disease (GVHD) Key Products
• Graft versus host disease (GVHD) Unmet Needs
• Graft versus host disease (GVHD) Market Drivers and Barriers
• Graft versus host disease (GVHD) Future Perspectives and Conclusion
• Graft versus host disease (GVHD) Analyst Views
• Appendix
Trending Reports:
• Menorrhalgia Market - https://www.delveinsight.com/report-store/menorrhalgia-market
• Complicated Intra-Abdominal Infections market - https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market
• Bronchial Spasm Market - https://www.delveinsight.com/report-store/bronchial-spasm-market
• Acute Radiation Syndrome Market - https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Age Related Vision Dysfunction Market - https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market
• Cerebral Aneurysm Market - https://www.delveinsight.com/report-store/cerebral-aneurysm-market
• Severe Hypoglycemia Market - https://www.delveinsight.com/report-store/severe-hypoglycemia-market
• Ada-Scid Competitive Landscape - https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
• DCSSC Market - https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market
• Bradykinesia Market - https://www.delveinsight.com/report-store/bradykinesia-market
Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft versus host disease Pipeline Report 2023: Treatment Drugs, Emerging Therapies with Over 60 Key Companies Working in the Domain by DelveInsight | Biocon, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, R here
News-ID: 3019171 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Graft
Bone Graft and Graft Substitute Market Latest Research, Top Impacting Factors, G …
The "Bone Graft and Graft Substitute Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. A bone graft is a surgical treatment used to repair problems with bones or joints. Bone grafting, or transplanting of bone tissue, is useful in fixing bones that are impaired from trauma or problem joints. Bone growth around an embedded…
Synthetic Bioactive Bone Graft Substitutes Market Growing need for bone graft su …
Global Synthetic Bioactive Bone Graft Substitutes Market Overview:
The Synthetic Bioactive Bone Graft Substitutes market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Synthetic Bioactive Bone Graft Substitutes market has experienced significant growth, driven by factors such as increasing consumer demand,…
Bone Graft Substitutes Market Size to Hit $3.8 Billion by 2028 | Bone Graft Subs …
Market Overview:
According to our experience research team, Bone Graft Substitutes Market was valued at USD 2.7 Billion in 2021, and the global Bone Graft Substitutes industry is projected to reach a value of USD 3.8 Billion by 2028, at a CAGR of 5.9% during the forecast period 2022-2028
Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology,…
Graft Delivery Devices Market Facts, Figures and Analytical Insights, 2017 to 20 …
Global Graft Delivery Devices Market: Snapshot
Graft delivery relates to the surgically transplantation of a piece of living tissues and the procedure can be highly essential as well as complex at the same time. Consequently, technological advancements have paved way to graft delivery devices that can minimally breach bone, fat, and vascular parts of the body to transfer drugs during plastic and reconstructive surgeries as well as arthroscopic and orthopedic surgeries.…
Glass Graft Polyols Market 2019| BASF SE, Sinopec, Shell, Oltchim, The Dow Chemi …
Market Research Hub (MRH) has actively included a new research study titled “Global Graft Polyols Market” Research Report 2019 to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until forecast period limit; 2025. In…
Global Vascular Graft Market Growth Analysis Report 2018-2025Global Vascular Gra …
Research Report 2018-2025 on "Global Vascular Graft Market" which provides an outlook of current market value of Vascular Graft Market as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% in Vascular Graft Market by the end of 2025. The report on the global Vascular Graft market uses the top-down and bottom-up approaches to define, analyze, and describe the Vascular Graft market 2018 trends…
